8月14日 - ** Beam Therapeutics BEAM.O股价盘前上涨2.11%，报17.89美元
** 生物技术公司称 (link)，美国FDA已授予其用于治疗镰状细胞病的实验性细胞疗法BEAM-101再生医学高级疗法(RMAT)。
** RMAT标签旨在支持再生医学（包括基因疗法）的开发和评估，以解决尚未满足医疗需求的严重或危及生命的疾病。
** 镰状细胞病是一种严重的遗传性血液病，会影响红细胞的形状，而红细胞能将氧气输送到身体的各个部位。
** 截至收盘，股价累计下跌 29
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.